GENFF
Price
$0.02
Change
-$0.00 (-0.00%)
Updated
Apr 10 closing price
Capitalization
5.3M
OCS
Price
$18.27
Change
+$0.25 (+1.39%)
Updated
Apr 17 closing price
Capitalization
876.96M
Ad is loading...

GENFF vs OCS

Header iconGENFF vs OCS Comparison
Open Charts GENFF vs OCSBanner chart's image
Genflow Biosciences
Price$0.02
Change-$0.00 (-0.00%)
Volume$20K
Capitalization5.3M
Oculis Holding AG
Price$18.27
Change+$0.25 (+1.39%)
Volume$25.93K
Capitalization876.96M
GENFF vs OCS Comparison Chart
Loading...
OCS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
GENFF vs. OCS commentary
Apr 18, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is GENFF is a Buy and OCS is a Hold.

Ad is loading...
COMPARISON
Comparison
Apr 18, 2025
Stock price -- (GENFF: $0.02 vs. OCS: $18.27)
Brand notoriety: GENFF and OCS are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: GENFF: 192% vs. OCS: 51%
Market capitalization -- GENFF: $5.3M vs. OCS: $876.96M
GENFF [@Biotechnology] is valued at $5.3M. OCS’s [@Biotechnology] market capitalization is $876.96M. The market cap for tickers in the [@Biotechnology] industry ranges from $282.79B to $0. The average market capitalization across the [@Biotechnology] industry is $2.08B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

GENFF’s FA Score shows that 0 FA rating(s) are green whileOCS’s FA Score has 0 green FA rating(s).

  • GENFF’s FA Score: 0 green, 5 red.
  • OCS’s FA Score: 0 green, 5 red.
According to our system of comparison, OCS is a better buy in the long-term than GENFF.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

OCS’s TA Score shows that 5 TA indicator(s) are bullish.

  • OCS’s TA Score: 5 bullish, 3 bearish.

Price Growth

GENFF (@Biotechnology) experienced а 0.00% price change this week, while OCS (@Biotechnology) price change was +13.13% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +7.02%. For the same industry, the average monthly price growth was -13.21%, and the average quarterly price growth was -24.46%.

Reported Earning Dates

OCS is expected to report earnings on Feb 28, 2023.

Industries' Descriptions

@Biotechnology (+7.02% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
OCS($877M) has a higher market cap than GENFF($5.3M). OCS YTD gains are higher at: 7.471 vs. GENFF (-71.808).
GENFFOCSGENFF / OCS
Capitalization5.3M877M1%
EBITDAN/A-84.89M-
Gain YTD-71.8087.471-961%
P/E RatioN/A63.08-
RevenueN/A0-
Total CashN/A98.7M-
Total DebtN/A1.18M-
TECHNICAL ANALYSIS
Technical Analysis
OCS
RSI
ODDS (%)
Bullish Trend 1 day ago
85%
Stochastic
ODDS (%)
Bearish Trend 1 day ago
36%
Momentum
ODDS (%)
Bullish Trend 1 day ago
51%
MACD
ODDS (%)
Bullish Trend 1 day ago
60%
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
50%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
46%
Advances
ODDS (%)
Bullish Trend 1 day ago
71%
Declines
ODDS (%)
Bearish Trend 11 days ago
62%
BollingerBands
ODDS (%)
Bullish Trend 1 day ago
58%
Aroon
ODDS (%)
Bearish Trend 1 day ago
37%
View a ticker or compare two or three
Ad is loading...
OCS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
EPSIX21.530.15
+0.70%
NYLI Epoch Global Equity Yield Inv Class
DOXWX13.810.09
+0.66%
Dodge & Cox Global Stock X
APHRX30.150.07
+0.23%
Artisan Global Opportunities Instl
JAMFX4.98N/A
N/A
Jacob Internet Inv
WEGRX10.71N/A
N/A
Allspring Emerging Growth R6

GENFF and

Correlation & Price change

A.I.dvisor tells us that GENFF and APLIF have been poorly correlated (+27% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that GENFF and APLIF's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To GENFF
1D Price
Change %
GENFF100%
N/A
APLIF - GENFF
27%
Poorly correlated
+12.73%
TOVX - GENFF
25%
Poorly correlated
+2.65%
VRCA - GENFF
23%
Poorly correlated
+2.36%
SGMT - GENFF
10%
Poorly correlated
+9.41%
OCS - GENFF
6%
Poorly correlated
+1.39%
More